Skip to content
type1.science

FreeStyle Libre 3 (original 14-day)

Abbott

What it is

The original 14-day Libre 3, distinct from the 15-day Plus. Abbott Germany still advertises a statutory-insurance prescription pathway, but stock and fulfilment are unconfirmed. US discontinuation and the Northern Ireland tariff withdrawal limit access; historical accuracy results belong to this generation.

Editorial review: . 16 September review-note archive (earlier notes may not cover later changes).

Most recent recorded citation date: 2026-09-15. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.

Trial status, labels and access can change between reviews. Review coverage and open work · How to read the evidence

Full sources ↓Full discussion ↓Report an issue →

Germany: advertised pathwayRegulator-approvedcgm

Evidence behind this assessment

Key evidence notes. Study results, product eligibility and access answer different questions.

Who was studied?
Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
Benefit or performance
Read the reported benefits in the full discussion. Effect sizes and study limitations are described there.
Important harms and treatment burden
Read the safety discussion and original sources. A missing summary does not establish safety.
Approval and country access
Abbott Germany lists a statutory-insurance prescription route. This has not independently confirmed stock or fulfilment. US discontinuation and Northern Ireland tariff withdrawal are documented.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
Follow-up and remaining uncertainty
Read the 16 September review-note archive and current review coverage for documented checks and their limits.

This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.

The full picture

This record is for the original, 14-day FreeStyle Libre 3, labeled from age 4, rather than the 15-day Libre 3 Plus. It preserves the correct generation for historical accuracy studies and country-specific access.12

Access: a limited, source-qualified listing

Abbott's German original-sensor page still advertises a statutory-insurance prescription-submission pathway. It separately says that private/self-pay purchases switched to Plus from 15 October 2024. This record's availability flag refers to that advertised German pathway only: the page is not independent confirmation that an original-sensor order will currently be fulfilled, or that stock exists. Confirm the prescribed generation with the supplier.1

In the US, Abbott says it is discontinuing original Libre 3 in favour of Plus; the checked FAQ does not establish an exact final-stock date. In the UK, the Northern Ireland BSO specifically removed original Libre 3 from its Drug Tariff from 1 April 2026 and directed a prescription transition to Plus. That official notice establishes Northern Ireland's reimbursement change, not a worldwide discontinuation date.34

What the original accuracy study found

The Abbott-funded original 14-day study enrolled 108 people; 100 were evaluable. The laboratory-reference analysis included 95 people aged 6+, with 6,845 pairs and overall 7.8% MARD. The adult subgroup had 56 participants and 7.5% MARD; 39 children aged 6–17 had 8.6%. Five children aged 4–5 contributed only 72 capillary-meter pairs, with 10.0% MARD. Their reference and small sample differ from the laboratory analysis. The 100 evaluable participants included 83 with type 1 and 17 with type 2 diabetes.5

The study did not deliberately manipulate glucose using meal/insulin challenges. Its mean lag estimate was 1.8 minutes, with a 4.8-minute standard deviation; this method-dependent estimate is not a guaranteed delay during rapid changes. Eight participants had mild or moderate device-related adverse events and no serious adverse events were reported. The study does not establish comparative everyday safety or universal accuracy.5

The current US label instead reports 6,836 laboratory pairs in 95 participants and 7.9% overall MARD. Its adult result is 7.6%, rather than the journal's 7.5%. This review has not reconciled the differing pair sets; these are attributed analyses, not interchangeable numbers. None is a Libre 3 Plus result.65

An Abbott-funded head-to-head study compared original Libre 3 with original Dexcom G7: 56 people enrolled and 55 contributed laboratory-reference data. MARD was 8.9% across 4,020 Libre pairs versus 13.6% across 3,640 G7 pairs. Abbott also designed, analysed and interpreted the study. Each device had only 35 pairs below 70 mg/dL (3.9 mmol/L) and one below 54 mg/dL (3.0 mmol/L), so it cannot establish hypoglycaemia superiority. These results must not be transferred to Plus or G7 15 Day.7

Label, compatibility and practical limits

Current US instructions give original Libre 3 a 14-day maximum, a 60-minute warm-up, and IP27 water resistance to 1 metre for 30 minutes. Factory calibration still requires meter backup when readings disagree with symptoms or expectations, no current number is available, or the first-12-hour inaccurate-sensor symbol appears. The original US sensor's vitamin C warning concerns more than 500 mg/day, a different threshold from Plus.6

The US original sensor is not labeled for AID. Separately, Abbott Germany documents original Libre 3 with mylife Loop, illustrating why US and European compatibility cannot be interchanged. Trio v1.0 also describes original Libre 3 direct support in beta, at five-minute cadence and without LibreView/LibreLink/LibreLinkUp upload. A community release is not regulator clearance.289

Safety notices

The 2025–26 incorrect-low-reading recall covers certain original Libre 3 as well as Plus sensors. Follow the FDA notice's serial-number check and stop-use/replacement instructions for affected sensors; an apparently normal reading does not establish that a recalled sensor is unaffected.10

A separate 2024 original-Libre-3 recall concerned incorrect high readings in model 72081-01, lots T60001948, T60001966 and T60001969. The FDA notice records Abbott's 24 July 2024 notification and instructs affected users to stop using/dispose of those sensors and obtain replacements through its linked checker. That historical action is distinct from the later incorrect-low-reading recall.11

References

  1. Abbott Germany — original Libre 3 sensor and statutory-insurance prescription pathway. ↩ ↩2

  2. FDA K233537 — original Libre 3 and Libre 3 Plus indications. ↩ ↩2

  3. Abbott US — why original Libre 3 sensors are being discontinued. ↩

  4. Northern Ireland BSO — original Libre 3 deletion from the Drug Tariff. ↩

  5. Accuracy of the Third Generation of a 14-Day Continuous Glucose Monitoring System. ↩ ↩2 ↩3

  6. Libre app US User Manual — ART48742-103 Rev A. ↩ ↩2

  7. Comparison of Point Accuracy Between Two Widely Used Continuous Glucose Monitoring Systems. ↩

  8. Abbott Germany — compatible automated insulin delivery systems. ↩

  9. Trio v1.0 release — direct Libre 3 and Libre 3 Plus support in beta. ↩

  10. FDA recall communication — certain Libre 3 and Libre 3 Plus sensors with incorrect low readings. ↩

  11. FDA recall — certain original Libre 3 sensors with incorrect high readings. ↩

Sources

  1. [1]Abbott Germany — original Libre 3 sensor and statutory-insurance prescription pathway · Manufacturer — Public page still advertises a statutory-insurance prescription pathway. A page listing is not independent confirmation of current stock or fulfilment.
  2. [2]Abbott US — why original Libre 3 sensors are being discontinued · Manufacturer
  3. [3]Northern Ireland BSO — original Libre 3 deletion from the Drug Tariff · Regulatory decision · 2026-03-13
  4. [4]FDA K233537 — original Libre 3 and Libre 3 Plus indications · Regulatory decision · 2024-04-23 — Plus is indicated from age 2 with compatible AID; the original US sensor is age 4+ and is not for AID.
  5. [5]Libre app US User Manual — ART48742-103 Rev A · Manufacturer — US labeling for original Libre 3 and Libre 3 Plus; indications and performance tables are separate.
  6. [6]Accuracy of the Third Generation of a 14-Day Continuous Glucose Monitoring System · Peer-reviewed study · 2023-03-06 — Original 14-day Libre 3; not a Libre 3 Plus accuracy trial. Abbott funded the study.
  7. [7]Comparison of Point Accuracy Between Two Widely Used Continuous Glucose Monitoring Systems · Peer-reviewed study · 2024-01-08 — Original Libre 3 versus original Dexcom G7. Abbott funded, designed, analysed and interpreted the study.
  8. [8]Abbott Germany — compatible automated insulin delivery systems · Manufacturer
  9. [9]Trio v1.0 release — direct Libre 3 and Libre 3 Plus support in beta · Open-source community · 2026-09-15
  10. [10]FDA recall communication — certain Libre 3 and Libre 3 Plus sensors with incorrect low readings · Regulatory decision · 2026-02-04 — February 4 is the communication update announcing Class I classification, not an independently established classification decision date.
  11. [11]FDA recall — certain original Libre 3 sensors with incorrect high readings · Regulatory decision